Patel spoke to Decider about collaborating with director Philip Barantini and Thorne (who’s adapted all three Enola Holmes ...

CNBC's Ritika Gupta speaks to John Swinney, Scotland's first minister, about the U.K.'s change of prime minister, further ...

Unilever's Rianne Buter explains why the firm has joined the 24/7 Coalition to ensure it can totally eliminate emissions from ...

In this video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights recent coverage of the myriad ways federal policies are impacting health care, from Medicare ...

Prometheus Co-Founders and Co-CEOs Jeff Bezos and Vik Bajaj sits down with CNBC's David Faber to talk Prometheus' strategy, the role AI plays in that strategy, its recent fundraising, and much more.

Highly touted prospect AJ Dybantsa provided some on-the-ground reporting as the New York Knicks made history with their 29-point comeback against the San Antonio Spurs in the 2026 NBA Finals. The ...

WASHINGTON – UFC Freedom 250 takes place Sunday at the White House with a card that streams on Paramount+. Before fight night arrives, though, notable athletes from the card, including headliners Ilia ...

LinkedIn has been a recurring source of breaches at AstraZeneca in recent years. The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K.

AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric for blood-sugar levels, by 1.9 percentage points on average in diabetic ...

Share on Pinterest AstraZeneca’s new oral GLP-1 pill showed promising results for weight loss and blood sugar in a phase 2 trial. Guido Mieth/Getty Images A new GLP-1 oral medication from AstraZeneca, ...

AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...